Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib followed by ofatumumab consolidation in previously untreated CLL/SLL
2016-004937-26Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- May 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib and ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Fundación PETHEMA. Primary endpoint: Complete response rate. Started May 2017; status: active.
02
Drugs
ibrutinibofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2016-004937-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004937-26.